Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Septra

PreclinicalSmall molecule

MMedical College of Wisconsin

Septra is one of 59 small molecule programs targeting Abscess. It is currently in Preclinical.

2

Indications

2

Total Trials

0

Active Trials

58

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

HypospadiasActive, not recruiting

AbscessPreclinical

Active, not recruiting

HypospadiasPreclinical

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Abscess

#DrugCompanyPhaseTrials

Valtrex

GGlaxo Dba Glaxosmithkline

Bactroban

Duragesic

Flagyl

DDePuy Orthopaedics

Naproxen Sodium

Activase

Biaxin

Primaxin

Mycobutin

Intranasal Ketamine

JJavelin Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypospadias1 trial

Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair

Completed·MMedical College of Wisconsin·N/A·NCT02593903·67 enrolled

Abscess1 trial

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

Completed·559th Medical Wing·N/A·NCT00829686·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Septra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Septra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Septra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical College of Wisconsin

Related News